Neurocrine biosciences presents additional phase 3 data for kinect-hd study evaluating valbenazine for chorea associated with huntington disease at hsg 2022

San diego , nov. 3, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the phase 3 kinect-hd study investigating valbenazine for the treatment of chorea associated with huntington disease (hd). in december 2021, neurocrine previously reported that once-daily administration of valbenazine was well tolerated with a statistically significant improvement in chorea associated with hd compared with placebo, along with substantial clinician- and patient-rated global improvement.
NBIX Ratings Summary
NBIX Quant Ranking